Edgewise Therapeutics, Inc. disclosure: Janus Henderson Group plc reported beneficial ownership of 5,915,556 shares of common stock, representing 5.5% of the class as of 03/31/2026. The filing states the Asset Managers exercise shared voting and dispositive power over these shares on behalf of Managed Portfolios. The Asset Managers disclaim rights to receive dividends or sale proceeds; the Managed Portfolios themselves have the rights to dividends and proceeds and, according to the filing, no single Managed Portfolio owns more than 5%.
Positive
None.
Negative
None.
Insights
Janus Henderson disclosed a >5% stake held through multiple asset managers.
The filing lists 5,915,556 shares (5.5%) and attributes shared voting and dispositive power to Janus Henderson's Asset Managers acting for Managed Portfolios as of 03/31/2026. Ownership is presented as agency-managed rather than direct proprietary stakes.
Implications depend on portfolio-level decisions; subsequent filings could show transfers among advisers or reductions. Future Schedule 13D/13G updates would reveal material changes in position or intent.
Key Figures
Filing date reference:03/31/2026Shares beneficially owned:5,915,556 sharesPercent of class:5.5%+2 more
5 metrics
Filing date reference03/31/2026date shown on Schedule 13G header
Shares beneficially owned5,915,556 sharesAmount reported as beneficially owned by Janus Henderson
Percent of class5.5%Percent of common stock represented by the reported shares
Shared voting power5,915,556 sharesShared power to vote or direct the vote reported in Item 4
Shared dispositive power5,915,556 sharesShared power to dispose or direct disposition reported in Item 4
"may be deemed to be the beneficial owner of 5,915,556 common stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Managed Portfoliosfinancial
"clients which include investment companies, other investment advisers, institutional separate accounts"
Shared Dispositive Powergovernance
"Shared power to dispose or to direct the disposition of: 5915556"
Schedule 13Gregulatory
"Item 1. (a) Name of issuer: EDGEWISE THERAPEUTICS, INC."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
What stake does Janus Henderson report in Edgewise Therapeutics (EWTX)?
Janus Henderson reports beneficial ownership of 5,915,556 shares, equal to 5.5% of Edgewise Therapeutics' common stock as of 03/31/2026. The position is held through multiple Asset Managers acting for Managed Portfolios.
Do the Janus Henderson entities have voting power over the EWTX shares?
Yes. The filing discloses shared voting power and shared dispositive power for 5,915,556 shares, indicating the Asset Managers exercise voting and disposition discretion on behalf of Managed Portfolios.
Who receives dividends or sale proceeds for the reported shares?
The filing states the Asset Managers do not have the right to receive dividends or sale proceeds; those rights belong to the underlying Managed Portfolios, per the disclosure in Item 6 of the Schedule 13G.
Does any single Managed Portfolio own more than 5% of EWTX?
According to the filing, none of the individual Managed Portfolios own more than 5% of Edgewise Therapeutics' common stock; the reported 5.5% is an aggregated beneficial ownership figure across managed accounts.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
EDGEWISE THERAPEUTICS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
28036F105
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
28036F105
1
Names of Reporting Persons
JANUS HENDERSON GROUP PLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,915,556.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,915,556.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,915,556.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
EDGEWISE THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
1715 38TH ST
BOULDER, CO 80301
Item 2.
(a)
Name of person filing:
Janus Henderson Group plc
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
28036F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 5,915,556 common stock of Edgewise Therapeutics, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
5.5 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
5915556
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
5915556
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, none own more than five percent of the common stock of Edgewise Therapeutics, Inc.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
